What is the prevalence of Glioma?

Glioma is a broad category of primary brain tumors that accounts for approximately 30% of all central nervous system tumors and 80% of all malignant brain tumors. While incidence rates are approximately 6 per 100,000 people annually, the prevalence varies significantly by subtype, with high-grade gliomas being more aggressive and low-grade gliomas showing longer survival times.

What is the incidence and prevalence of Glioma?

The incidence of Glioma is estimated at roughly 6 cases per 100,000 individuals per year, according to the Central Brain Tumor Registry of the United States (CBTRUS). Because Glioma encompasses various grades (I-IV), prevalence is difficult to determine as a single figure; patients with low-grade tumors may live for many years, while those with glioblastoma—the most common and aggressive form—have much shorter survival rates. Data suggests that while these tumors are not considered "rare" in the context of neuro-oncology, they are rare compared to systemic cancers.

Who is most commonly affected by Glioma?

Epidemiological patterns for Glioma show distinct demographic trends:

• Gender: These tumors are slightly more common in males than in females across most age groups.


• Age: While Glioma can occur at any age, the peak incidence for high-grade tumors is in adults aged 65 to 75, whereas certain low-grade subtypes are more frequently diagnosed in children and young adults.


• Geography/Ethnicity: Incidence rates are highest in North America and Northern Europe, though it is unclear if this reflects true biological differences or variations in diagnostic reporting and healthcare access.

Why is gathering accurate data for Glioma challenging?

Tracking the exact prevalence of Glioma is complicated by evolving classification systems. The World Health Organization (WHO) periodically updates the criteria for Glioma diagnosis based on molecular markers like IDH mutation status. These changes mean that historical data may not align with current diagnostic standards, leading to potential undercounting or misclassification of specific subtypes.

What does the DiseaseMaps community experience show?

At DiseaseMaps.org, 34 people with Glioma have joined the community to share their personal journeys. This real-world data provides a vital perspective that complements clinical statistics, highlighting the diverse lived experiences of patients navigating treatment, symptom management, and the long-term emotional impact of a Glioma diagnosis.

Next steps

• Consult a neuro-oncologist to discuss your specific tumor grade and molecular profile.


• Join the DiseaseMaps.org community to connect with others sharing similar clinical experiences.


• Inquire about clinical trials through the National Cancer Institute (NCI) if you are seeking novel therapeutic options.

Medical disclaimer: This content is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• Central Brain Tumor Registry of the United States (CBTRUS) Statistical Report.


• National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD).


• World Health Organization (WHO) Classification of Tumours of the Central Nervous System.


• Orphanet: Information on rare diseases and orphan drugs.